S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.

In an exploratory finding, tumors with high Ki-67 (≥30%) or small initial size of tumor (≤2 cm) showed a trend toward a higher pCR rate than those without but they did not reach statistical significance (Table 3 ).

also in 53,322 other papers